

# eTab Pharma Limited

Annual Report and Financial Statements  
for the Year Ended 30 April 2018

## **eTab Pharma Limited**

### **Profit and Loss Account for the Year Ended 30 April 2018**

The company has not traded during the year. During this year, the company received no income and incurred no expenditure and therefore made neither profit nor loss.

The notes on pages 3 to 4 form an integral part of these financial statements.

**eTab Pharma Limited**  
**(Registration number: 08017992)**  
**Balance Sheet as at 30 April 2018**

	Note	2018 £	2017 £
<b>Current assets</b>			
Debtors	<u>3</u>	<u>100</u>	<u>100</u>
<b>Capital and reserves</b>			
Called up share capital	<u>4</u>	<u>100</u>	<u>100</u>
Total equity		<u>100</u>	<u>100</u>

For the financial year ending 30 April 2018 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Director's responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

Approved and authorised by the director on 14 November 2018

.....  
Mr C Wilson

Director

The notes on pages 3 to 4 form an integral part of these financial statements.  
Page 2

# eTab Pharma Limited

## Notes to the Financial Statements for the Year Ended 30 April 2018

### 1 General information

The company is a private company limited by share capital incorporated in England and Wales.

The address of its registered office is:

3 Manor Court  
Dunstall Road  
Barton under Needwood  
Burton on Trent  
Staffordshire  
DE13 8AU  
United Kingdom

These financial statements were authorised for issue by the director on 14 November 2018.

### 2 Accounting policies

#### Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

#### Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

#### Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

#### Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

### 3 Debtors

	Note	2018 £	2017 £
Amounts owed by related parties		100	100
Total current trade and other debtors		100	100

## eTab Pharma Limited

### Notes to the Financial Statements for the Year Ended 30 April 2018

#### 4 Share capital

##### Allotted, called up and fully paid shares

	2018		2017	
	No.	£	No.	£
Ordinary share of £1 each	100	100	100	100

---

---

#### 5 Parent undertaking and ultimate controlling interest

The company's immediate parent is eTab Health Group Limited, incorporated in England and Wales.  
The ultimate controlling party is Mr C Wilson.

Page 4

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.